Allogene Therapeutics delivered early Phase 2 efficacy data for cema-cel, its off-the-shelf CAR-T program in first-line consolidation large B-cell lymphoma (LBCL). In the company’s reported interim futility analysis, seven of 12 treated patients achieved minimal residual disease (MRD) negativity at day 45, compared with two of 12 in an observation arm. Allogene framed the MRD clearance difference as aligning with published literature suggesting it may translate into clinically meaningful relapse-delay potential, though full Phase 2 completion results are still pending. The company also said the treatment profile included mostly low-grade neurological effects in half of patients, with severe events reported as limited. The data come as allogeneic cell therapy remains a high-profile strategy to reduce the complexity and time constraints of personalized CAR-T manufacturing.